NCT01835041View on ClinicalTrials.gov

CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

February 28, 2017

Study Completion Date

March 16, 2023

Conditions
Acinar Cell Adenocarcinoma of the PancreasDuct Cell Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage IV Pancreatic Cancer
Interventions
DRUG

6,8-bis(benzylthio)octanoic acid

Given IV

DRUG

oxaliplatin

Given IV

DRUG

leucovorin calcium

Given IV

DRUG

irinotecan hydrochloride

Given IV

DRUG

fluorouracil

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

27157

Comprehensive Cancer Center of Wake Forest University, Winston-Salem

All Listed Sponsors
lead

Wake Forest University Health Sciences

OTHER

collaborator

National Cancer Institute (NCI)

NIH

NCT01835041 - CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter